Sorintellis
Sorintellis is a Montreal-based AI software company that builds TrialsBank™, a proprietary clinical development data foundation, and sells D.O.P.E. AI solutions to pharmaceutical companies, life sciences investment funds, and CROs for clinical trial design, risk prediction, and portfolio management.
- Company typePrivate
- Founded2022
- HeadquartersMontréal, Canada
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Sorintellis does
Sorintellis Group Inc is a Montreal-based, privately held AI software company founded in 2022 that builds clinical drug development intelligence infrastructure for the pharmaceutical industry. The company's product is centered on TrialsBank™, a proprietary, deeply curated clinical development data foundation integrating multi-dimensional data across scientific, clinical, operational, regulatory, and financial domains, and trained on hundreds of thousands of curated clinical trials. On top of TrialsBank™, Sorintellis sells two AI-powered solutions — D.O.P.E. for Clinical Trials (covering Design, Optimize, Prioritize, and Execute phases) and D.O.P.E. for Pharmaceutical Portfolio Management (enabling scenario simulation and dynamic optimization across assets, indications, and development pathways) — combining predictive and causal AI to support trial design, risk prediction, resource allocation, and portfolio strategy decisions.
The company serves three primary customer segments: pharmaceutical companies (with Pfizer as a named collaboration partner), life sciences investment funds seeking asset valuation and portfolio management, and contract research organizations (CROs) executing clinical trials. Sorintellis operates an enterprise-focused direct sales motion with a "Request a demo" funnel and quote-based pricing; pricing is not publicly disclosed and no published revenue, ARR, or funding rounds are on record. The company has built a dense ecosystem of strategic collaborators, including Université de Montréal, Université Laval, Polytechnique Montréal, Mila (Quebec AI Institute), IVADO, HEC Montréal, Vantage Biotrials, CQDM, MITACS, Pfizer, BioQuebec, and Amorchem, which provide research validation, talent pipelines, and grant/co-development funding. Recognition includes finalist status in the ADRIQ Prix Innovation 2025 and inclusion in HackerNoon's global winning startup list.
Sorintellis firmographics
Firmographics- Name
- Sorintellis
- Legal name
- Sorintellis Group Inc
- Website
- https://sorintellisgroup.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Sorintellis is a Montreal-based AI software company that builds TrialsBank™, a proprietary clinical development data foundation, and sells D.O.P.E. AI solutions to pharmaceutical companies, life sciences investment funds, and CROs for clinical trial design, risk prediction, and portfolio management.
- Ownership category
- akta.pro rank
Sorintellis industry classification
Industry- Product category
- Clinical Trial Intelligence / Pharmaceutical R&D Analytics
- NAICS
- Computer Systems Design Services (541512), Scientific Research and Development Services (5417)
- SIC
- Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
Keywords
Where Sorintellis is headquartered
LocationHeadquarters
- HQ city
- Montréal
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Sorintellis business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- AI Platform/SaaS Subscription: Likely subscription-based access to TrialsBank™ platform and D.O.P.E. solutions for pharmaceutical portfolio management and clinical trial intelligence.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Sorintellis product offering
Product offeringCore offering
Sorintellis provides an AI-powered clinical development intelligence platform anchored by its proprietary TrialsBank™ data foundation, which integrates multi-dimensional data across scientific, clinical, operational, regulatory, and financial domains. The platform delivers two solutions under the D.O.P.E. methodology (Design, Optimize, Prioritize, Execute): one for clinical trial intelligence and one for pharmaceutical portfolio management, enabling optimized protocol design, risk prediction, asset valuation, and portfolio strategy simulation for pharmaceutical companies, life sciences investment funds, and CROs.
Product overview
Sorintellis offers a unified platform architecture centered on TrialsBank™ as the core data intelligence infrastructure, with two primary AI-powered solutions built upon it: D.O.P.E. for Clinical Trials and D.O.P.E. for Pharmaceutical Portfolio Management. TrialsBank™ provides the curated clinical development data foundation that powers both solutions, enabling AI-driven applications across trial design, execution, risk prediction, asset valuation, and portfolio optimization.
Differentiator
Problem solved
Functional benefit
Brands
- TrialsBank™: A deeply curated and validated clinical development data foundation that integrates multi-dimensional data across scientific, clinical, operational, regulatory, and financial domains to enable advanced AI applications for clinical development.
Products and services
- TrialsBank™ Proprietary, deeply curated and validated clinical development data foundation that integrates multi-dimensional data across scientific, clinical, operational, regulatory, and financial domains; serves as the structured intelligence layer powering all Sorintellis AI applications. Built and validated over years, providing the context required to uncover true drivers of trial outcomes beyond what is available in public databases. Aimed at pharmaceutical companies, life sciences investment funds, and CROs.
- D.O.P.E. for Clinical Trials
- D.O.P.E. for Pharmaceutical Portfolio Management
Companies that use Sorintellis
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Sorintellis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Sorintellis partnerships and signals
Strategic signalPartnerships
18 partnerships are on record, tiered core and minor.
- Université de MontréalcoreAcademic partnership in strategic scientific collaboration to advance TrialsBank™-powered clinical trial intelligence. Contributes academic expertise from leading Quebec research institution.
- Université LavalcoreAcademic partner in strategic collaboration developing AI-driven recommendation engines for clinical trial decision-making, portfolio strategy, and valuation.
- Mila - Quebec Artificial Intelligence InstitutecoreAI research institute partnership for developing recommendation engines to optimize clinical development across trial design, operational execution, and portfolio strategy.
- IVADOcoreStrategic scientific collaboration with IVADO (Institute for Data-Driven Value Creation) to advance clinical trial intelligence layer powered by TrialsBank™.
- Vantage BiotrialscoreClinical trial execution expertise partner joining AI collaboration to advance clinical trial intelligence and improve trial execution with TrialsBank™.
- IVADO, Polytechnique Montréal, Université de MontréalcorePartnership to transform pharmaceutical portfolio management through AI with MITACS support. Decision-making system development for strategic portfolio management.
- PfizercoreCollaboration to develop AI-based platform aimed at efficiently mitigating risks in clinical drug development.
- CQDMcoreCo-funding development of AI-powered platform to mitigate clinical trial risks, including funding for research and development.
- MITACScoreAcademic research partnership supporting AI training and development of solutions for strategic pharmaceutical portfolio management based on clinical trial success estimation.
- MilacorePartnership to optimize complex decision-making processes in clinical drug development using AI and machine learning.
- Polytechnique MontréalcoreAcademic partner in AI-driven pharmaceutical portfolio management transformation with MITACS support.
- Prompt InnovminorFeatured on Prompt Innov platform with CEO interview and project coverage.
- Quebec Ministry of EconomyminorPartner logo displayed indicating government/regional support.
- BrouilletteminorPartner logo displayed on website.
- BioQuebecminorQuebec biotech industry association partnership.
- HEC MontréalminorAcademic partner from Quebec business school.
- AmorchemminorPartner logo displayed - Quebec-based biotech investment firm.
- CTS SantéminorPartner logo displayed - health sector organization.
Scale indicators2 records
Recent moves6 records
Expansion highlights6 records
Sorintellis competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key highlights7 records
Customer concentration
Sorintellis social profiles
Digital presenceSorintellis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sorintellis leadership team
Management profileNumber of profiles
Profiles2 records
Sorintellis funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sorintellis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sorintellis
What does Sorintellis do?
Sorintellis provides an AI-powered clinical development intelligence platform anchored by its proprietary TrialsBank™ data foundation, which integrates multi-dimensional data across scientific, clinical, operational, regulatory, and financial domains. The platform delivers two solutions under the D.O.P.E. methodology (Design, Optimize, Prioritize, Execute): one for clinical trial intelligence and one for pharmaceutical portfolio management, enabling optimized protocol design, risk prediction, asset valuation, and portfolio strategy simulation for pharmaceutical companies, life sciences investment funds, and CROs.
Is Sorintellis a public or private company?
Sorintellis is a private company. It is classified as unknown and is currently operating.
When was Sorintellis founded?
Sorintellis was founded in 2022. It employs 1 to 10 people.
Where is Sorintellis based?
Sorintellis is headquartered in Montréal, Canada, in the North America region.
How does Sorintellis make money?
One revenue line is on record: AI Platform/SaaS Subscription.
Does Sorintellis have an API?
No public API is recorded for Sorintellis.
What industry is Sorintellis in?
Sorintellis's product category is Clinical Trial Intelligence / Pharmaceutical R&D Analytics. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 541512 and its SIC code is 7372.